ABOUT Michael Morris Buchman

Michael Buchman has more than 20 years of experience, primarily litigating antitrust, consumer protection and privacy class actions in trial and appellate courts.

Michael has a diverse antitrust background, having represented as lead or co-lead counsel a variety of plaintiff clients, from Fortune 500 companies to individual consumers, in complex cases covering matters such as restraint of trade, price-fixing, generic drug antitrust issues and anticompetitive “reverse payment” agreements between brand name pharmaceutical companies and generic companies. Michael leads Motley Rice’s antitrust team.

Michael served as an Assistant Attorney General in the New York State Attorney General’s Office, Antitrust Bureau, after receiving his LL.M. degree in International Antitrust and Trade Law. Also prior to joining Motley Rice, he was a managing partner of the antitrust department at a New York-based class action law firm. He played an active role in resolving two of the largest U.S. multi-billion dollar antitrust settlements since the Sherman Act was enacted, In re NASDAQ Market-Makers Antitrust Litigation and In re Visa Check/Mastermoney Antitrust Litigation, as well as litigated numerous multi-million dollar antitrust cases. Today, he represents the largest retailer class representative in the 6.2 billion case In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation, MDL 1720.

Michael has more than 18 years of experience representing consumers, union health and welfare plans, and health insurers in “generic drug” litigation such as In re Augmentin Antitrust Litigation, In re Buspirone Antitrust Litigation, In re Ciprofloxacin Antitrust Litigation, In re Flonase Antitrust Litigation, In re K-Dur Antitrust Litigation, In re Relafen Antitrust Litigation, In re Tamoxifen Antitrust Litigation, In re Toprol XL Antitrust Litigation and In re Wellbutrin SR Antitrust Litigation. He also has experience litigating a large aviation antitrust matter, as well as aviation crash, emergency evacuation and other aviation cases in federal and state court.

Michael completed the intensive two-week National Institute for Trial Advocacy National Trial Training program in Boulder, Colo., in 2002. An avid writer, he has authored and co-authored articles on procedure and competition law, including a Task Force on Dealer Terminations for The Association of the Bar of the City of New York, Committee on Antitrust and Trade Regulation, entitled Dealer Termination in New York dated June 1,1998 and What’s in a Name - the Diversity Death-Knell for Underwriters of Lloyd’s of London and their Names; Humm v. Lombard World Trade, Inc., Vol. 4, Issue 10 International Insurance Law Review 314 (1996).

Michael is active in his community, serving as a member of the Flood and Erosion Committee for the Town of Westport, Ct., and as pro bono counsel in actions involving the misappropriation of perpetual care monies. He has also coached youth ice hockey teams at Chelsea Piers in New York City.

Prior results do not guarantee a similar outcome.

Awards and Accolades

•Best Lawyers

2017-2020 Mass tort litigation/class actions - plaintiffs

•Super Lawyers

2014-2019 New York Metro Super Lawyers list - Antitrust


2019 Lawdragon 500 Plaintiff Financial Lawyers

Related Content

Recent Blog Posts

September 2, 2016

The 400 Percent Question: Why so few generic alternatives to Mylan’s EpiPen?

by: Michael M. Buchman

December 16, 2014

Pleading antitrust injury in the absence of FDA approval of a drug

by: Michael M. Buchman

Related News

March 30, 2020

Loestrin antitrust litigation settlement reached

February 14, 2020

Law360 names Motley Rice a 2019 Product Liability Practice Group of the Year

January 22, 2020

Motley Rice wins two “Elite Trial Lawyers” Firm of the Year categories

View More

Contact Us

    Please prove you are human by selecting the House.